Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

- 1.-15. (Cancelled).
- 16. (Currently Amended) A method for treating a mammal suffering from a localized bacterial infection or a bacterial-related disease comprising administering a therapeutically effective amount of a composition comprising at least one Colony Stimulating Factor (CSF) granulocyte-macrophage-colony stimulating factor (GM-CSF) polypeptide or fragment or derivative thereof having essentially the biological function and activity of the CSF GM-CSF.
- 17. (Previously Presented) The method of claim 16, wherein the bacterial infection or bacterial-related disease is selected from periodontal disease or sinusitis.
- 18. (Previously Presented) The method of claim 17, wherein the periodontal disease is gingivitis or periodontitis.
- 19. -20. (Cancelled).
- 21. (Previously Presented) The method of claim 16, wherein the composition is suitable for administration via injection through the mucosal lining of the gingival or by application in a periodontal pocket.
- 22. (Currently Amended) The method of claim 16, wherein the CSF GM-CSF or fragment or derivative thereof is present in the composition in a unit dosage amount of 5 µg to 800 µg.

Applicant : Henrik Arnberg Attorney's Docket No.: 15665-Serial No. : 10/599,753 010US1 / PD53824US00

Serial No.: 10/599,753 Filed: July 25, 2007

Page : 3 of 5

23. (Previously Presented) The method of claim 22, wherein the unit dosage amount is 50 μg to 100 μg .

- 24. (Previously Presented) The method of claim 16, wherein the composition is administered at intervals ranging from once a day to once every third week.
- 25. (Previously Presented) The method of claim 16, wherein the composition is administered a total of 1 to 3 times for a period of one week.
- 26. (Previously Presented) The method of claim 16, wherein the composition comprises a therapeutically effective amount of at least one other active ingredient.
- 27. (Currently Amended) The method of claim 16, wherein the CSF GM-CSF or fragment or derivative thereof is produced by means of a recombinant expression system.
- 28. (Cancelled).
- 29. (Previously Presented) A composition for treating a localized bacterial infection or bacterial related disease comprising a therapeutically effective amount of a granulocyte-macrophage-colony stimulating factor (GM-CSF) polypeptide or fragment or derivative thereof.